Navigation Links
AviaraDx Presents at 2007 BIOCOM Investor Conference
Date:10/5/2007

Newly formed molecular diagnostic company launches two oncology tests

SAN DIEGO, Oct. 5 /PRNewswire/ -- AviaraDx, Inc., announced today that the company is scheduled to provide a corporate overview of its molecular diagnostic test offerings and development programs at the 2007 BIOCOM Investor Conference. The presentation is scheduled for Thursday, November 1st, at 2:30 p.m. in the Rancho Santa Fe ballroom of the San Diego Marriott Del Mar Hotel, 11966 El Camino Real, San Diego, CA 92130.

About AviaraDx, Inc.

AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient's tumor. Our tests improve the classification of cancer, support physicians to provide their patients with a more specific prognosis or individual risk assessment, and will provide information critical to predict treatment response to a given therapeutic regimen. AviaraDx offers diagnostic tests to qualified physicians or laboratories through its CAP-certified CLIA laboratory service operations. The company's first diagnostic test offerings are based on its proprietary technologies for the molecular classification of metastatic cancer, CancerTYPE ID(TM), and its H/I(TM) (HOXB13/IL17BR) test to assess risk of recurrence and response to endocrine therapy in certain breast cancer patients.

CONTACT:

Antonius Schuh, Ph.D.

Chief Executive Officer

+1 (760) 579 0500

aschuh@aviaradx.com


'/>"/>
SOURCE AviaraDx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
8. International Conference On Malaria - Laveran To Genomics
9. African Conference to Combat AIDS
10. International conference on Ayurveda to be held on Kerala
11. 5th European Breast Cancer Conference Talks about Everything from Patient to Oncologist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... announced today the addition of an affiliate in Minneapolis-St. Paul, MN, Dr. Adam ... accelerated detox, Naltrexone therapy and aftercare planning through his Timewise Medical practice in ...
(Date:9/25/2017)... ... 2017 , ... SyncDog, Inc., the leading ISV ... will be available in a managed cloud services model, available from its new ... new enhancements including support for caller ID and network sharing for remote users, ...
(Date:9/25/2017)... Church, VA (PRWEB) , ... September 25, 2017 ... ... & Trump, **An FDAnews Webinar**, Oct. 12, 2017 — 1:30 p.m. – 3:00 ... off to a running start. Just look what’s happened in four short months:, ...
(Date:9/25/2017)... ... September 25, 2017 , ... The award is named in honor of Betty ... year the award is given to those who exemplify the mission of Community Options ... in communities of their choosing. Recent recipients of this award include Governor Tom Kean, ...
(Date:9/25/2017)... ... September 25, 2017 , ... Just ask anyone old enough ... or 1980s, with headgear so wired up and containing so much metal that jokes ... so discreet that its treatments can barely be observed. As a result, it’s now ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
Breaking Medicine Technology: